🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Anticoagulant-related bleeding: 30-day incidence of mortality was 19.4% in patients with solid tumors. ICH alone increased risk of mortality 6-fold and GI bleeding 3-fold. Prediction of these adverse events could improve survival. #Hematology #Oncology doi.org/10.1002/ajh.27…

One of the best thrombosis programs in the world Marc Carrier Deborah Siegal Tzu-Fei Wang Université d'Ottawa | University of Ottawa

Did you know? Around 50% of patients with acute CAT in your practice do not meet the inclusion criteria of the RCTs. Listen to the podcast with Geoff Barnes about recent trials taking a more pragmatic approach. Medthority medthority.com/medical-educat…

Marc Carrier Geoff Barnes Medthority And those interested in the CAT trends in the 20 past years (doi: 10.1016/j.jaccao.2023.09.003) :

Cancer-associated thrombosis is not only about venous events. Patients with cancer and no prior strokes have a 1.5 ⬆️risk of ischemic stroke compared to those without cancer. ⬆️risk with certain cancer types sciencedirect.com/science/articl… JTH CanVECTOR Network Thrombosis Canada

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! thelancet.com/journals/lance… Francis Couturaud

The Repeat Study addressed a really important knowledge gap! The incidence of recurrent events following an ante- or postpartum VTE is 2.4% person-years. The cumulative risks are 6%, 13%, 17%, and 30% at 2, 5, 10, and 30 years respectively. jthjournal.org/article/S1538-…

Post-hoc analysis of the Hokusai VTE Cancer trial showed that treatment for recurrent VTE on AC were heterogeneous, and there were high risks of second recurrent VTE (9%) and major bleeding (10%) within 3 months! doi.org/10.1016/j.jtha… JTH Gary Raskob Marc Carrier

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Don’t miss it! Our HemeHub session with Dr. Marc Carrier on Thrombophilia Testing is tomorrow. A great chance to learn, connect, and ask your questions live. See you there!

Have you ever wondered about the long-term risk of recurrence in patients with isolated SSPE? New data suggest the risk may not exceed the threshold for extended duration anticoagulation. Case by case decision is needed. 👉sciencedirect.com/science/articl… Thrombosis Canada CanVECTOR Network

🎉 Celebrating the end of a remarkable year with our uOttawa | Faculté de médecine, Faculty of Medicine Adult Thrombosis Medicine International Fellows! We're incredibly proud of all you've achieved and the impact you've made. Thank you for your dedication and excellence. 🌍🩸 🇨🇦🇺🇾🇨🇭🇫🇷🇧🇪🇸🇦🇮🇹🇺🇦

Thank you to all of the Team Thrombosis Canada members who participated in the Tamarak Ottawa Charity Challenge on the weekend and raised $6,150 to support our efforts. Thanks also to everyone who donated, it's greatly appreciated. #Thrombosis #CharityChallenge #Support